Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03656692 · ClinicalTrials.gov registry record · Phase 4
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
A Phase 4 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03656692 is a Phase 4 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 5 participants.
The verdict
NCT03656692, a Phase 4 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
Interventions
- DRUG Acthar Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-10-05 |
| Est. Completion | 2020-07-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03656692
The ClinicalTrials.gov registry entry for NCT03656692 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acthar Gel is the first listed.
NCT03656692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03656692 about?
NCT03656692 is a clinical study titled "Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)". The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
What is the current status of trial NCT03656692?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2018-10-05. Estimated completion is 2020-07-14.
What interventions are being tested in trial NCT03656692?
The interventions under investigation include: Acthar Gel (DRUG).
Who is sponsoring clinical trial NCT03656692?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.